Neuren Pharmaceuticals Limited announced the cessation of Dr. John Douglas Wilson as director, effective May 20, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.34 AUD | +1.68% | -7.73% | -22.55% |
05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.55% | 1.61B | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.72% | 246B | |
+10.80% | 213B | |
-3.03% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Announces the Cessation of John Douglas Wilson as Director